Recursion Pharmaceuticals
recursion-pharmaceuticals-67074d1e·2 events·first seen 15d agoAliases: Recursion Pharmaceuticals
Co-occurring entities
More like this (12)
Recent events (2)
US Government Prepares AI Model Vetting System; GPT-5.5 Instant, Claude Finance Agents, Pentagon AI Partnerships
The White House is preparing an executive order to create an FDA-style vetting system for new AI models, prompted partly by Anthropic's Mythos model disclosing cybersecurity risks; the Commerce Department separately expanded a voluntary testing program with Google, Microsoft, and xAI. OpenAI rolled out GPT-5.5 Instant as the default ChatGPT model, claiming 52.5% fewer hallucinations on high-stakes prompts. Anthropic released ten financial agent templates running on Claude Opus 4.7, while the Pentagon expanded AI vendor agreements to include Microsoft, Amazon, Nvidia, and Reflection AI after canceling its Anthropic contract over autonomous weapons restrictions. Major pharma companies report AI gains primarily in manufacturing optimization rather than drug discovery breakthroughs.
Eli Lilly Commits Up to $2.75 Billion to Insilico Medicine for AI-Driven Drug Discovery
Eli Lilly agreed to pay up to $2.75 billion to Insilico Medicine, a Hong Kong biotech using generative AI across its drug-discovery pipeline, with an initial $115 million for exclusive rights to undisclosed pre-clinical drug candidates. Insilico's platform uses PandaOmics for target identification and Chemistry42 for molecule design, reducing the time from target identification to preclinical candidates from 5-6 years to roughly 18 months and screening far fewer compounds than conventional methods. The deal is the third between the companies and follows positive Phase 2a results for Rentosertib, an AI-discovered drug targeting idiopathic pulmonary fibrosis. No AI-discovered drug has yet received regulatory approval, and the key open question is whether AI-accelerated compounds will show higher clinical trial success rates than traditionally developed drugs.